AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6873851 — intervention group
Group type: EXPERIMENTAL
Intervention: Both new suppository preparations
Number of subjects: 0
Study 30219772 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg
Number of subjects: 3492
Study 30219772 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg
Number of subjects: 3492
Study 30219772 — intervention group
Group type: EXPERIMENTAL
Intervention: All-bari-RA (any baricitinib dose)
Number of subjects: 3492
Study 29503371 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial exercises program (30 min, twice a week for 12 weeks)
Number of subjects: 75
Study 27177079 — intervention group
Group type: EXPERIMENTAL
Intervention: Group schema therapy (ST)
Number of subjects: 42
Study 25493600 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple maternal antiretrovirals (zidovudine, lamivudine, and either nevirapine, nelfinavir, or lopinavir-ritonavir)
Number of subjects: 1479
Study 25493600 — intervention group
Group type: COMPARATOR
Intervention: Daily infant nevirapine
Number of subjects: 1479
Study 22377796 — intervention group
Group type: EXPERIMENTAL
Intervention: Black currant anthocyanins (BCACs) 50 mg/day (n = 19)
Number of subjects: 38
Study 22377796 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 19)
Number of subjects: 38
Study 19700304 — intervention group
Group type: COMPARATOR
Intervention: Sustained-release oral oxycodone 20mg followed by immediate-release oxycodone 10mg 6-hourly for the first 24h (group O)
Number of subjects: 120
Study 19700304 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 100mug (group I)
Number of subjects: 120
Study 18355324 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin (low-dose cohort: 2.5, 5, 10, 20 or 40 mg once daily for 12 weeks)
Number of subjects: 423
Study 18355324 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin (high-dose cohort: 100 mg once daily for 6 weeks)
Number of subjects: 423
Study 18355324 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin (both cohorts)
Number of subjects: 423
Study 18355324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 423
Study 15821191 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery (LVRS)
Number of subjects: 93
Study 15821191 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy
Number of subjects: 93
Study 12425782 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational outreach visits by pharmacists
Number of subjects: 102
Study 10802002 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 35
Study 10802002 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment
Number of subjects: 35
Study 8894886 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary nursing
Number of subjects: 161
Study 8894886 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 161
Study 1800760 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol 100 mg twice daily (n = 30)
Number of subjects: 61
Study 1800760 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) 25 mg twice daily (n = 31)
Number of subjects: 61
Study 6331783 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (32 patients)
Number of subjects: 72
Study 6331783 — intervention group
Group type: COMPARATOR
Intervention: Placebo (39 patients)
Number of subjects: 72
Study 6331783 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (10 patients with gastric ulcer)
Number of subjects: 72
Study 6331783 — intervention group
Group type: COMPARATOR
Intervention: Placebo (12 patients with gastric ulcer)
Number of subjects: 72
Study 12529075 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (4.0 mg/kg)
Number of subjects: 42
Study 12529075 — intervention group
Group type: COMPARATOR
Intervention: Placebo caffeine
Number of subjects: 42
Study 29995947 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-dialytic low-frequency electrical muscle stimulation (LF-EMS)
Number of subjects: 64
Study 29995947 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-dialytic cycling
Number of subjects: 64
Study 29995947 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise control
Number of subjects: 64
Study 27167369 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep dry needling (DDN) combined with rehabilitation
Number of subjects: 20
Study 27167369 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation alone
Number of subjects: 20
Study 24815571 — intervention group
Group type: EXPERIMENTAL
Intervention: Community engagement and service-strengthening intervention
Number of subjects: 0
Study 24815571 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no intervention)
Number of subjects: 0
Study 22185894 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined sleep hygiene education and behavioral approach program (30 min) including relaxation training, stimulus control, and sleep restriction.
Number of subjects: 2
Study 22185894 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 2
Study 20420475 — intervention group
Group type: EXPERIMENTAL
Intervention: Step‐down model (CP) consisting of initial short‐term day hospital treatment followed by conjoint group and individual outpatient treatment
Number of subjects: 114
Study 20420475 — intervention group
Group type: COMPARATOR
Intervention: Outpatient individual psychotherapy (OIP)
Number of subjects: 114
Study 19105001 — intervention group
Group type: EXPERIMENTAL
Intervention: Chaplain interventions (5 visits, average total visit time 44 min)
Number of subjects: 166
Study 19105001 — intervention group
Group type: COMPARATOR
Intervention: Control group (no chaplain visits)
Number of subjects: 166
Study 16062017 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (200 mg orally) followed by misoprostol (800 micro gm intravaginally)
Number of subjects: 100
Study 16062017 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (50 mg/m2 intramuscularly) followed by misoprostol (800 micro gm intravaginally)
Number of subjects: 100
Study 12231310 — intervention group
Group type: EXPERIMENTAL
Intervention: Opegan (low-molecular-weight sodium hyaluronate 1%)
Number of subjects: 136
Study 12231310 — intervention group
Group type: COMPARATOR
Intervention: Healon (high-molecular-weight sodium hyaluronate 1%)
Number of subjects: 136
Study 10202166 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (40 mg/m² once a week for up to six doses during radiotherapy)
Number of subjects: 369
Study 10202166 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 369
Study 7599666 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous oral bromocriptine (2.5-10.0 mg/day) during two consecutive 30-day periods (T-1 and T-2)
Number of subjects: 14
Study 7599666 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent oral bromocriptine (from day 1 to 15 of each 30-day period)
Number of subjects: 14
Study 7599666 — intervention group
Group type: COMPARATOR
Intervention: Control period (no treatment)
Number of subjects: 14
Study 7599666 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (1 and 2) after treatment
Number of subjects: 14
Study 2403953 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-sized adenomas
Number of subjects: 1867
Study 2403953 — intervention group
Group type: EXPERIMENTAL
Intervention: Large adenomas
Number of subjects: 1867
Study 2403953 — intervention group
Group type: EXPERIMENTAL
Intervention: Villous A adenomas
Number of subjects: 1867
Study 2403953 — intervention group
Group type: EXPERIMENTAL
Intervention: Villous B adenomas
Number of subjects: 1867
Study 2403953 — intervention group
Group type: EXPERIMENTAL
Intervention: Villous C and D adenomas
Number of subjects: 1867
Study 2403953 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-sided location of adenomas
Number of subjects: 1867
Study 2403953 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiplicity of adenomas
Number of subjects: 1867
Study 2403953 — intervention group
Group type: EXPERIMENTAL
Intervention: Age greater than or equal to 60 years
Number of subjects: 1867
Study 2403953 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender (men)
Number of subjects: 1867
Study 318952 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (400 mg/day)
Number of subjects: 24
Study 318952 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (100 mg/day)
Number of subjects: 24
Study 318952 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 24
Study 31177924 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (100 mg rectal)
Number of subjects: 100
Study 31177924 — intervention group
Group type: COMPARATOR
Intervention: Glycerin suppository (placebo)
Number of subjects: 100
Study 28947465 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous hyperosmolar therapy (20% NaCl) plus standard care
Number of subjects: 370
Study 28947465 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 370
Study 25032123 — intervention group
Group type: EXPERIMENTAL
Intervention: N‐acetyl‐cysteine (NAC) (1200 mg/day)
Number of subjects: 48
Study 25032123 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginseng (200 mg/day)
Number of subjects: 48
Study 25032123 — intervention group
Group type: COMPARATOR
Intervention: Control (no antioxidant drugs)
Number of subjects: 48
Study 23424164 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 100 mg BID
Number of subjects: 314
Study 23424164 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 150 mg BID
Number of subjects: 314
Study 23424164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314
Study 23424164 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine 4 mg ER
Number of subjects: 314
Study 19952809 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen topical gel
Number of subjects: 106
Study 19952809 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 106
Study 18511165 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) for 4 weeks
Number of subjects: 24
Study 18511165 — intervention group
Group type: COMPARATOR
Intervention: Control group (sleep hygiene education only)
Number of subjects: 24
Study 16570267 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating Disorder (ED) memoir
Number of subjects: 50
Study 16570267 — intervention group
Group type: COMPARATOR
Intervention: Control memoir
Number of subjects: 50
Study 14528947 — intervention group
Group type: EXPERIMENTAL
Intervention: New automatic matching procedure using chamfer matching with additional information on gradient angle and magnitude of edges
Number of subjects: 29
Study 14528947 — intervention group
Group type: COMPARATOR
Intervention: Regular chamfer matching
Number of subjects: 29
Study 11228952 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror therapy
Number of subjects: 1
Study 9201012 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including in-hospital counseling, smoking cessation videotape, self-help literature, nicotine replacement therapy, and 3 months of telephone follow-up
Number of subjects: 324
Study 9201012 — intervention group
Group type: COMPARATOR
Intervention: Self-help literature and brief counseling lasting 10 minutes
Number of subjects: 324
Study 8067229 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine + Ephedrine
Number of subjects: 32
Study 8067229 — intervention group
Group type: COMPARATOR
Intervention: Morphine alone
Number of subjects: 32
Study 3177858 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive spirometer as part of postoperative chest physiotherapy
Number of subjects: 40
Study 3177858 — intervention group
Group type: COMPARATOR
Intervention: Routine postoperative physiotherapy as dictated by needs
Number of subjects: 40
Study 5345935 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-monthly chest radiographs
Number of subjects: 100
Study 5345935 — intervention group
Group type: COMPARATOR
Intervention: Control group (no x-ray facilities)
Number of subjects: 100
Study 5345935 — intervention group
Group type: EXPERIMENTAL
Intervention: Resected lung cancer in test series
Number of subjects: 100
Study 5345935 — intervention group
Group type: COMPARATOR
Intervention: Resected lung cancer in control series
Number of subjects: 100
Study 5345935 — intervention group
Group type: EXPERIMENTAL
Intervention: Squamous carcinoma in test series
Number of subjects: 100
Study 5345935 — intervention group
Group type: COMPARATOR
Intervention: Squamous carcinoma in control series
Number of subjects: 100
Study 5345935 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenocarcinoma in test series
Number of subjects: 100
Study 5345935 — intervention group
Group type: COMPARATOR
Intervention: Adenocarcinoma in control series
Number of subjects: 100
Study 31614308 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer influence and peer selection
Number of subjects: 656
Study 31614308 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental smoking
Number of subjects: 656
Study 31614308 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal data analysis
Number of subjects: 656
Study 31614308 — intervention group
Group type: EXPERIMENTAL
Intervention: Best friend and friends' influence
Number of subjects: 656
Study 31614308 — intervention group
Group type: EXPERIMENTAL
Intervention: Friends and same grade students' influence
Number of subjects: 656
Study 31743406 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% povidone-iodine eye drops
Number of subjects: 100
Study 31743406 — intervention group
Group type: COMPARATOR
Intervention: Balanced salt solution eye drops
Number of subjects: 100
Study 28676009 — intervention group
Group type: EXPERIMENTAL
Intervention: Substitute tear + probiotic mixture (Saccharomyces boulardii MUCL 53837 and Enterococcus faecium LMG S‐28935)
Number of subjects: 60
Study 28676009 — intervention group
Group type: COMPARATOR
Intervention: Substitute tear (control)
Number of subjects: 60
Study 26212719 — intervention group
Group type: COMPARATOR
Intervention: Compression socks (SOCK)
Number of subjects: 20
Study 23620478 — intervention group
Group type: EXPERIMENTAL
Intervention: Normoalbuminuria with DR (NA(DR+))
Number of subjects: 1475
Study 23620478 — intervention group
Group type: EXPERIMENTAL
Intervention: Microalbuminuria without DR (MA(DR−))
Number of subjects: 1475
Study 23620478 — intervention group
Group type: EXPERIMENTAL
Intervention: Microalbuminuria with DR (MA(DR+))
Number of subjects: 1475
Study 23620478 — intervention group
Group type: COMPARATOR
Intervention: Normoalbuminuria without DR (NA(DR−))
Number of subjects: 1475
Study 21368587 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 600 mg
Number of subjects: 329
Study 21368587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 329
Study 21368587 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg
Number of subjects: 329
Study 21368587 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 450 mg
Number of subjects: 329
Study 19709795 — intervention group
Group type: EXPERIMENTAL
Intervention: PMA (physician-manned ambulance)
Number of subjects: 977
Study 19709795 — intervention group
Group type: COMPARATOR
Intervention: non-PMA (paramedic-manned ambulance)
Number of subjects: 977
Study 17897512 — intervention group
Group type: EXPERIMENTAL
Intervention: Early hip spica cast
Number of subjects: 0
Study 17897512 — intervention group
Group type: EXPERIMENTAL
Intervention: External fixator
Number of subjects: 0
Study 15838366 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitaxsentan (SITAX)
Number of subjects: 0
Study 15838366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11512646 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium 1.0 mg x kg(‐1)
Number of subjects: 120
Study 11512646 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium 0.4 mg x kg(‐1)
Number of subjects: 120
Study 11512646 — intervention group
Group type: COMPARATOR
Intervention: Edrophonium doses (0.1, 0.2, 0.4, 1 mg x kg(‐1))
Number of subjects: 120
Study 11512646 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.1 mg x kg(‐1)
Number of subjects: 120
Study 11512646 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium (dose not specified)
Number of subjects: 120
Study 8826506 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical capsaicin cream applied 3 times daily for 5 weeks
Number of subjects: 0
Study 8826506 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream applied 3 times daily for 5 weeks
Number of subjects: 0
Study 1728876 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral labetalol
Number of subjects: 36
Study 1728876 — intervention group
Group type: COMPARATOR
Intervention: Oral clonidine
Number of subjects: 36
Study 3909798 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (60 mg/m2 I.V. day 1, observation after 500 mg/m2)
Number of subjects: 151
Study 3909798 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin (40 mg/m2 I.V. day 1; maximum 500 mg/m2) and mitolactol (135 mg/m2 orally, days 1‐10; 180 mg/m2 after maximum doxorubicin)
Number of subjects: 151
Study 31454159 — intervention group
Group type: EXPERIMENTAL
Intervention: Ball abutments
Number of subjects: 90
Study 31454159 — intervention group
Group type: EXPERIMENTAL
Intervention: Locator abutments
Number of subjects: 90
Study 31454159 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (balls and locators)
Number of subjects: 90
Study 29503247 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave ablation
Number of subjects: 152
Study 29503247 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency ablation
Number of subjects: 152
Study 26921676 — intervention group
Group type: EXPERIMENTAL
Intervention: PZQ/ART
Number of subjects: 913
Study 26921676 — intervention group
Group type: COMPARATOR
Intervention: PZQ/ART-placebo
Number of subjects: 913
Study 24669876 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine 400 mg/day
Number of subjects: 267
Study 24669876 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone 15 mg/day
Number of subjects: 267
Study 22879929 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive anidulafungin treatment based on BDG surveillance
Number of subjects: 64
Study 22879929 — intervention group
Group type: COMPARATOR
Intervention: Empiric antifungal treatment based on physician preference
Number of subjects: 64
Study 19955453 — intervention group
Group type: EXPERIMENTAL
Intervention: Champions leading infection prevention efforts
Number of subjects: 86
Study 19955453 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral change implementation
Number of subjects: 86
Study 19955453 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of organizational networks
Number of subjects: 86
Study 17181848 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus position at 3 o'clock
Number of subjects: 31
Study 17181848 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus position at 9 o'clock
Number of subjects: 31
Study 17181848 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus position at 6 o'clock
Number of subjects: 31
Study 17181848 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus position at 12 o'clock
Number of subjects: 31
Study 15094440 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc‐labelled human albumin colloid with a particle size of 0.2‐3 microm (Albu‐Res)
Number of subjects: 119
Study 15094440 — intervention group
Group type: COMPARATOR
Intervention: 99mTc‐labelled albumin colloid with a particle size of < 80 nm (Nanocoll)
Number of subjects: 119
Study 11268714 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (100 mg two to three times daily)
Number of subjects: 72
Study 11268714 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide (40-80 mg twice daily)
Number of subjects: 72
Study 9850256 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional eye pad and shield
Number of subjects: 83
Study 9850256 — intervention group
Group type: COMPARATOR
Intervention: Clear eye shield applied without a pad
Number of subjects: 83
Study 10525491 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic VVI pacing
Number of subjects: 32
Study 10525491 — intervention group
Group type: EXPERIMENTAL
Intervention: Reestablishment of chronic AV synchrony with DDD pacing
Number of subjects: 32
Study 10525491 — intervention group
Group type: COMPARATOR
Intervention: Chronic DDD pacing
Number of subjects: 32
Study 2404386 — intervention group
Group type: EXPERIMENTAL
Intervention: Method I: Two catheter electrodes (right ventricular cathode and right atrial anode)
Number of subjects: 12
Study 2404386 — intervention group
Group type: EXPERIMENTAL
Intervention: Method II: One catheter electrode and cutaneous patch (right ventricular cathode and cutaneous apical patch anode)
Number of subjects: 12
Study 418655 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest radiography
Number of subjects: 0
Study 418655 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 0
Study 31383231 — intervention group
Group type: EXPERIMENTAL
Intervention: NightBalance sleep position treatment (SPT) device
Number of subjects: 117
Study 31383231 — intervention group
Group type: COMPARATOR
Intervention: Auto-adjusting positive airway pressure (APAP)
Number of subjects: 117
Study 28208806 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose OP beverage (77% OP)
Number of subjects: 34
Study 28208806 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose OP beverage (35% OP)
Number of subjects: 34
Study 28208806 — intervention group
Group type: COMPARATOR
Intervention: Placebo (255 g)
Number of subjects: 34
Study 25988560 — intervention group
Group type: EXPERIMENTAL
Intervention: pre‐S vaccine
Number of subjects: 82
Study 25988560 — intervention group
Group type: COMPARATOR
Intervention: Engerix B
Number of subjects: 82
Study 23471586 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluven 5 ml/kg
Number of subjects: 60
Study 23471586 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluven 7 ml/kg
Number of subjects: 60
Study 23471586 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluven 9 ml/kg
Number of subjects: 60
Study 20674978 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of close social network members
Number of subjects: 115
Study 20674978 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related support from social network members
Number of subjects: 115
Study 20032539 — intervention group
Group type: EXPERIMENTAL
Intervention: AZT/lamivudine/efavirenz (n=15)
Number of subjects: 32